Pulmera, an emerging medical technology company developing next-generation intraoperative imaging solutions, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for its CBeam™ 3D imaging platform.

Pulmera will take the stage at LSI USA ’26 as CEO Kevin McGann presents the company’s innovative C-Beam™ technology on March 19, 2026.